Early Pseudoprogression After Tarlatamab in Small-Cell Lung Cancer: A Case Report.

Respirol Case Rep · 2025 · PMC12358216 · PMID 40827251

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

The absolute lymphocyte count in peripheral blood showed a decreasing trend, from 1091/μL before the administration of tarlatamab to 902/μL on Day 5 and 690/μL on Day 12 post‐treatment.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.